A Vision of the Future of Interventional Cardiology: EuroPCR 2025 Congress Report
From May 19 to 22, EuroPCR 2025—the world’s leading course in interventional cardiovascular therapy—was held in Paris, France. As one of the largest global congresses dedicated to minimally invasive procedures, EuroPCR attracts physicians and healthcare professionals from around the world to exchange insights on the latest advancements in interventional cardiovascular therapies. This year, the event welcomed a record-breaking 12,177 attendees, reflecting a growing interest in this ever-evolving field.
Canon showcased the latest innovations of the Alphenix / Evolve Edition through its exhibition booth and a dedicated off-site symposium.
Canon showcased the latest innovations of the Alphenix / Evolve Edition through its exhibition booth and a dedicated off-site symposium.
Innovative Booth Experience
This year, Canon introduced a dedicated Experience Room, allowing visitors to review clinical images with the newly released second-generation αEvolve Imaging. Attendees from across Europe, as well as Australia, Pakistan, Saudi Arabia, and Malaysia, participated in a structured survey to evaluate the clinical value of this new imaging technology.
The feedback was highly positive, not only regarding the image quality, but also toward Canon’s forward-thinking concept of “DA-less intervention”. This approach, which emphasizes reduced reliance on digital acquisitions (DA), resonated strongly with interventional cardiologists and clinicians seeking to minimize radiation exposure while maintaining high procedural confidence.
The feedback was highly positive, not only regarding the image quality, but also toward Canon’s forward-thinking concept of “DA-less intervention”. This approach, which emphasizes reduced reliance on digital acquisitions (DA), resonated strongly with interventional cardiologists and clinicians seeking to minimize radiation exposure while maintaining high procedural confidence.
Offsite Symposium: “Activating AI for DA-Less Procedures”
Canon hosted an off-site symposium at Le Méridien Etoile, targeting international healthcare professionals with a strong interest in advancing interventional cardiology and radiation dose management. The objective was to deepen understanding of the clinical value of the Alphenix / Evolve Edition and to encourage active dialogue among healthcare professionals.
αEvolve Imaging utilizes Deep-Learning based noise reduction and multi-frequency processing to enable outstandingly clear fluoroscopic imaging, which can deliver up to two times higher contrast-to-noise ratio compared to conventional image processing.
αEvolve Imaging utilizes Deep-Learning based noise reduction and multi-frequency processing to enable outstandingly clear fluoroscopic imaging, which can deliver up to two times higher contrast-to-noise ratio compared to conventional image processing.
DA-less Intervention concept: By performing procedures using fluoroscopy alone or with minimal use of digital acquisition, the total radiation dose per case can be significantly reduced without altering established clinical workflows.
DA-less Intervention concept: By performing procedures using fluoroscopy alone or with minimal use of digital acquisition, the total radiation dose per case can be significantly reduced without altering established clinical workflows.
“Evolution 2010 to Now”
An expert in radiation dose management and a three-time recipient of the Best Scientific Abstract Award in the Nurses and Allied Professionals (NAPs) section of EuroPCR (2017, 2023, and 2025), Mr. Ison opened the symposium with an overview of Canon’s commitment to reducing radiation exposure in cardiovascular procedures. He described radiation exposure as “an invisible danger received throughout an interventionalist’s working life, insidious, often forgotten, and downplayed,” emphasizing the critical importance of optimizing dose levels in daily practice. He also presented preliminary findings from ongoing research with Dr. Pasupati, reporting a 41% reduction in radiation dose per coronary angiography case when using αEvolve Imaging.
Pioneer data from Waikato Hospital, New Zealand. Data demonstrated a 41% reduction in dose area product (DAP) per coronary angiography case.
Pioneer data from Waikato Hospital, New Zealand. Data demonstrated a 41% reduction in dose area product (DAP) per coronary angiography case.
“Every 3 cases on an Alphenix / Evolve Edition using fluoroscopy, you save a whole case worth of doses.”
Mr. Glenn Ison, Medical Radiation Scientist, Sydney, Australia
“Alphenix / Evolve Edition is Changing My Daily Practice”
Prof. Pawlowski, who also serves as Secretary of the Polish Cardiac Society, shared real-world cases using the Alphenix / Evolve Edition since introducing the system to his facility.
Incorporating an interactive quiz, his engaging session clearly demonstrated how the system is transforming diagnostic and interventional workflows in daily clinical practice.
Incorporating an interactive quiz, his engaging session clearly demonstrated how the system is transforming diagnostic and interventional workflows in daily clinical practice.
Comparison between digital acquisition and αEvolve Imaging fluoro images for the same patient. αEvolve Imaging achieves equivalent image quality comparable with digital acquisition while reducing radiation dose by approximately 80%.
Comparison between digital acquisition and αEvolve Imaging fluoro images for the same patient. αEvolve Imaging achieves equivalent image quality comparable with digital acquisition while reducing radiation dose by approximately 80%.
“We are still analyzing the data, but looking at diagnostic angiographic cases for this short period experience, there is a reduction in dose of more than 20%.”
Prof. Tomasz Pawlowski, National Institute of Medicine of the Ministry of Internal Affairs and Administration, Warsaw, Poland
“Step into the Future of Interventional Cardiology with DA-less Procedures”
Dr. Pasupati, who has been involved in numerous first-in-human trials and serves as a proctor for various interventional devices around the world, began evaluating the second-generation αEvolve Imaging recently. He presented his initial clinical experiences, including a standout case involving a 108 kg patient, whose procedure was completed entirely under fluoroscopy without any digital acquisitions, demonstrating the full potential of DA-less Intervention.
With unique solutions like αEvolve Imaging utilizing advanced AI technologies, Canon remains committed to advancing interventional cardiology through ongoing innovation and close collaboration with clinical partners across the globe. //
With unique solutions like αEvolve Imaging utilizing advanced AI technologies, Canon remains committed to advancing interventional cardiology through ongoing innovation and close collaboration with clinical partners across the globe. //
DA-less PCI procedure in a 76-Year-Old, 108 kg Male with Inferior STEMI. The entire case was performed only under fluoroscopy.
DA-less PCI procedure in a 76-Year-Old, 108 kg Male with Inferior STEMI. The entire case was performed only under fluoroscopy.
“In this era, patients are getting bigger while stents are getting thinner, and cath-labs demand image quality, less radiation, speed, and efficiency. All of these are answered by αEvolve Technology.”
Dr. Sanjeevan Pasupati, Director of Structural Heart Disease & Cardiovascular Research, Waikato Hospital, Hamilton, New Zealand
Due to medical device regulatory reasons, not all products/service displayed on this Canon Medical Systems ANZ webpage are available in all countries, regions or markets. Future availability of the products/service cannot also be guaranteed. Please contact your local Canon Medical Systems representative for further details.
